What happened with YI today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
111, Inc. helps pharmacies in China stock the medicines they sell. Through its online wholesale platform, 1 Pharmacy, it buys products from pharmaceutical companies and distributors, then resells them to independent pharmacies, chains and pharmacies inside clinics and private hospitals. It is responsible for filling and delivering these orders. Sales to pharmacy customers account for nearly all its revenue, making it primarily a pharmaceutical distributor rather than a consumer healthcare service.
Its smaller consumer business, 1 Medicine Marketplace, sells medicines and other health products directly and hosts third-party sellers that pay commissions and platform fees. Pharmaceutical companies also pay for services such as product promotion and sales-data analysis.
The wholesale business depends on keeping pharmacy customers, offering competitive prices, matching inventory to demand and getting orders delivered through third-party couriers. Its drug wholesale, retail and online platform activities require Chinese licenses and regulatory permissions. Rules govern online prescription-drug sales, and it may not publish prescription-drug advertisements on its website.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
111, Inc.’s results depend mainly on Chinese pharmacies’ purchasing and wholesale distribution competition; watch Ali Health for competition in its much smaller online retail business.
Ridgetech is a closer comparison for 111, Inc.’s main business: both distribute medicines in China, with Ridgetech selling to local buyers offline and nationwide online, while 111 buys medicines and resells them to pharmacies and distributors. Watch Ridgetech’s wholesale sales and distribution margins for clues to the business that generated 97.5% of 111’s net revenue in 2025.
JD.com competes for consumers buying medicines online with 111, Inc., but 111’s consumer product sales accounted for only 1.8% of net revenue in 2025. JD.com also hosts 111’s branded storefront and collects a percentage of its sales, so it is both a retail rival and a paid sales channel for this smaller business.
JD.com, Inc. earningsJD
JD.com’s report will show how consumers are buying medicines through its online channel, which competes with 111, Inc. and also hosts 111’s branded storefront.
Look for changes in JD.com’s online medicine sales, separating its own retail from marketplace activity if the report provides that detail. Stronger sales would suggest online medicine demand is holding up; growth in the marketplace hosting 111’s storefront could also support that store’s sales and the percentage-based commissions 111 earns. Weaker sales would point to pressure on online demand, affecting both 111’s consumer competition and its route to shoppers through JD.com. JD.com’s overall results alone cannot establish how 111’s storefront performed.
111, Inc. earningsThis company
Pharmacy product sales make up nearly all of 111, Inc.’s revenue, and this report will show whether pharmacies are still buying through its platform.
Watch the trend in B2B product revenue alongside service revenue. Stabilizing B2B sales with steady services would suggest pharmacy purchasing and income from commissions and digital marketing are holding up; further B2B declines, even with services steady, would show the core wholesale channel remains under pressure.
